Cannabix Technologies Announces Key Hardware
Advancements to Marijuana Breathalyzer Technology
Vancouver, British Columbia, Canada -- January 9, 2025 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix")
developer of marijuana and alcohol breath testing devices is
pleased to report that it has made significant updates to its
Cannabix Marijuana Breathalyzer ("CMB") technology to meet
suggested emerging regulatory requirements in preparation for
marketing. Cannabix engineers have incorporated several new
features to the Company's Breath Collection Unit ("BCU") – a
critical hardware tool used for portable collection of delta-9 THC
in breath (images below). These developments come as the need
for marijuana breath detection gains intensity in the United States
and globally.
Cannabix Breath Collection Unit ("BCU") with
Breath Cartridge technology.
A recently
published New York Times article, "As Marijuana Use
Grows, Effect on Road Safety Remains a Blind Spot"
(January 2025) highlights U.S. federal
research into road safety and cannabis use, and the lack of tools
to detect cannabis-impaired driving (1). Furthermore, the article
discusses the limitations of existing testing methods for delta-9
THC and the increasing number of Americans consuming cannabis. The
article references a 2019 survey by the AAA Foundation for
Traffic Safety where an estimated 14.8 million drivers (in the
U.S) reported getting behind the wheel within one hour after using
marijuana, and 70% of Americans thinking it's unlikely a driver
will get caught by police for driving while high on marijuana (2).
Cannabix's marijuana breathalyzer technology is focused on "recent
use" detection of delta-9 THC as opposed to widely used urine,
blood and saliva methods (that can detect delta-9 THC many hours,
days, or even weeks after consumption) (3).
Rav Mlait,
CEO of Cannabix stated, "Cannabix is at the forefront of marijuana
breathalyzer technology, and we anticipate that 2025 will hold
significant milestones as the Company has matured its technology,
partnerships and business opportunities. In the U.S., cannabis
legalization has grown to 39 states for medical use and 24 states
legalized for recreational use. This represents a major growth
opportunity for Cannabix in the drug testing segment."
New Cannabix Breath Collection Unit ("BCU")
with Breath Cartridge technology.
Highlights:
-
Cannabix provides updated images of
its Breath Collection Unit ("BCU") and
Breath Cartridge
technology with several new features to the
Company's marijuana breathalyzer technology to meet industry and
suggested emerging regulatory requirements.
-
Major updates and improvements for the BCU
include a smaller, lightweight, more ergonomic design and new
removable, long-lasting, rechargeable Li-ion battery, allowing for
easy battery replacement.
-
The sample collection cartridge has been
modified to be able to collect a single sample or dual sample
consistent with federally regulated programs that require a
simultaneous A & B sample collection. Furthermore, a new
ambient air collection through a second cartridge is now
available.
-
New "on demand" periodic quality assurance
check, a new startup self-check feature, and streamlined user
interface.
-
Cannabix is quickly advancing its marijuana
breathalyzer technology, with key validation work well underway in
the United States.
References:
(1)
https://www.nytimes.com/2025/01/01/us/marijuana-driving-impairment.html
(2) https://newsroom.aaa.com/2019/06/americans-dont-think-theyll-get-arrested-for-driving-high/
(3) Olla P, Ishraque MT,
Bartol S. 2020. Evaluation of Breath and Plasma
Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in
Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol
breathalyzer technologies for law enforcement, workplaces and
laboratories. Cannabix is developing delta-9 THC and alcohol
screening devices. Delta-9 THC is the primary
psychoactive ingredient in cannabis. Breath testing for
delta-9 THC would allow employers and law enforcement
to identify recent marijuana use. Cannabix is the developer of
its Breath Logix Series of breath alcohol
detection devices for employers and a range of other
settings.
We seek Safe Harbor.
On behalf of the
Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information,
contact the Company at info@cannabixtechnologies.com
Cautionary Statement
Regarding Forward-Looking Statements
This news release contains certain
"forward-looking statements" within the meaning of such statements
under applicable securities law. Forward-looking statements are
frequently characterized by words such as "anticipates," "plan,"
"continue," "expect," "project," "intend," "believe," "anticipate,"
"estimate," "may," "will," "potential," "proposed," "positioned"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements in
this news release include, but are not limited to, statements
relating to: the achievement of any or all of the goals and aims
of partnerships as
described in this news release; final development of a commercial
or prototype product(s); the successful trial or pilot of company
technologies; the commercialization of the Company's products; the
negotiation and potential entry into additional agreements with
existing and new partners; and the completion of future financings.
There are numerous risks and uncertainties that could cause actual
results and the Company's plans and objectives to differ materially
from those expressed in the forward-looking information. Important
factors that could cause actual results to differ materially from
those expressed in the forward-looking information include (but are
note limited to): adverse market conditions; risks regarding
protection of proprietary technology; the ability of the Company to
complete future financings; the ability of the Company to develop
and market its future product; risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition; that partners may not complete
all or any of the milestones as contemplated strategic partnership
agreements; that the CSE may not approve the issuance of the
securities; that the Company's development of breathalyzer
technology will provide any benefit to the Company; there is no
assurance that any proposed new products will be built, will be
successful in beta testing or clinical trials; there is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies; there is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities; the Company is not
currently selling breathalyzers and there is no assurance that the
Company ever will; and other factors beyond the control of the
Company. Actual results and future events could differ materially
from those anticipated in such information. These and all
subsequent written and oral forward-looking information are based
on estimates and opinions of management on the dates they are made
and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
501-3292 Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
